Disruptive technologies and emerging trends drive life science transformation
New business models and behavioural shifts create opportunities for growth.
Across Life Sciences, disruptive technologies and behavioural shifts are driving the transformation of business models, while emerging trends are creating growth opportunities throughout the industry. To take advantage of these opportunities and maintain a competitive advantage, companies must fully understand areas outside their expertise. Corporations failing to capitalize on opportunities will be late entrants to a market and lose out on the market share.
New analysis from Frost & Sullivan, 2016 Global Life Sciences Predictions (https://utm.io/256547), finds disruptive technologies and emerging trends will create growth opportunities for research tools, clinical diagnostics and pharmaceuticals.
Through growth opportunities, the Life Sciences industry will experience
"Emerging business models, such as Precision Medicine, NGS Informatics Tools & Services and Contract Development and Manufacturing Organization (CDMO) have enabled a paradigm shift from broad therapies to targeted therapies, transforming the clinical practice and treatment outcomes," said Frost & Sullivan Transformational Health Research Manager Sangeetha Prabakaran. "A better understanding of disease heterogeneity and identification of novel targets will foster collaboration between pharmaceutical companies, diagnostic manufacturers, payers and providers to develop new products and services."
Furthermore, the Life Sciences industry is expected to advance with the integration of multi-disciplinary capabilities in biology, chemistry and computational power, which a company can leverage to develop new solutions to treat complex diseases. This will create new growth opportunities, enabling companies to maximize product quality at the lowest cost.
"Shifting payment business models will determine who pays for healthcare services; it will be challenging to monetize innovative therapeutics, biosimilars and molecular diagnostics to align with value-based care models," noted Frost & Sullivan Transformational Health Global Vice President Nitin Naik.
For future endeavours, CEOs should closely watch companies Foundation Medicine and Rain Dance Technologies; research tools companies Eagle Genomics and DNA Nexus; pharmaceutical companies Actavis and Innovio; and CDMOs Patheon and Catalent.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.